Objectives To evaluate the added benefit and revenues of oncology drugs, explore their association, and investigate potential discrepancies between added benefit and revenues across different approval pathways of the European Medicines Agency (EMA).
Design Retrospective cohort study.
Setting Oncology drugs and their indications approved by the EMA between 1995 and 2020.
Main outcome measures Added benefit was evaluated using ratings published by seven organisations: health technology assessment agencies from the United States, France, Germany, and Italy, two medical oncology societies, and a drug bulletin. All retrieved ratings were recategorised using a four point ranking scale to indicate negative or non-quantifiable, minor, substantial, or major added benefit. Revenue data were extracted from publicly available financial reports and compared with published estimates of research and development (R&D) costs. Finally, the association between added benefit and revenue was evaluat
As antibiotic resistance increases globally, antibiotic innovation is struggling.
WHO states that the antibiotic clinical pipeline is “insufficient to tackle the challenge
of increasing emergence and spread of antimicrobial resistance”.1 To prevent the development
of resistance, new antibiotics are used as last resort treatments and, if properly
used, have small patient populations, resulting in fairly low sales revenues for industry.
The RC72 sought and reached a consensus on key actions in several priority health areas, including those of particular interest for EPHA and its members.
New WHO Access Platform Could Mean Tiered Pricing In Europe informa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from informa.com Daily Mail and Mail on Sunday newspapers.